Mon, January 12, 2009
Sun, January 11, 2009
Fri, January 9, 2009
Thu, January 8, 2009
Wed, January 7, 2009
Tue, January 6, 2009
Mon, January 5, 2009
[ Mon, Jan 05th 2009 ] - Market Wire
Avexa and Progen Merger Update
Fri, January 2, 2009
Thu, January 1, 2009
Wed, December 31, 2008
[ Wed, Dec 31st 2008 ] - Market Wire
Obesity Comes With a Price Tag
Tue, December 30, 2008
Mon, December 29, 2008
Wed, December 24, 2008
Tue, December 23, 2008
Mon, December 22, 2008
Sun, December 21, 2008
Fri, December 19, 2008

Seattle Genetics to Present at the J.P. Morgan Healthcare Conference


//health-fitness.news-articles.net/content/2009/ .. ent-at-the-j-p-morgan-healthcare-conference.html
Published in Health and Fitness on , Last Modified on 2009-01-06 07:03:09 by Market Wire   Print publication without navigation


BOTHELL, Wash.--([ BUSINESS WIRE ])--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the 27th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2009, at 3:00 p.m. Pacific Time. A live webcast of the presentation will be available from Seattle Genetics' website, [ www.seattlegenetics.com ], under the "News and Investor Information" section. The conference is being held at the Westin St. Francis Hotel in San Francisco, California.

About Seattle Genetics

Seattle Genetics is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company has four product candidates in ongoing clinical trials: dacetuzumab (SGN-40), lintuzumab (SGN-33), SGN-35 and SGN-70. Dacetuzumab is being developed under a worldwide collaboration with Genentech. In addition, the company has developed proprietary antibody-drug conjugate (ADC) technology comprising highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics, Daiichi Sankyo and MedImmune, a subsidiary of AstraZeneca, as well as an ADC co-development agreement with Agensys, a subsidiary of Astellas Pharma. More information can be found at [ www.seattlegenetics.com ].


Publication Contributing Sources

Similar Health and Fitness Publications